

Transmitter Biochemistry of Human Brain Tissue

**Edited by
Peter Riederer
Earl Usdin**

TRANSMITTER BIOCHEMISTRY OF HUMAN BRAIN TISSUE

Proceedings of the Symposium held at the
12th CINP Congress, Göteborg, Sweden
June, 1980

Edited by

PETER RIEDERER

*Institute of Clinical Neurobiology,
Vienna*

and

EARL USDIN

*National Institute of Mental Health,
Rockville, Maryland*

M

This book was edited by Dr Usdin in
his private capacity. No official support
or endorsement by the NIMH is intended or
should be inferred.

© The Contributors 1981

All rights reserved. No part of this publication may be reproduced or transmitted, in any form or by any means, without permission

First published 1981 by
Scientific and Medical Division
MACMILLAN PUBLISHERS LTD
London and Basingstoke
Companies and representatives throughout the world
Printed by J. W. Arrowsmith Ltd., Bristol BS3 2NT

ISBN 0 333 31089 6

Participants

Dr Anne C. Andorn
Department of Pharmacology
Case Western Reserve University
School of Medicine
Cleveland, Ohio 44106

Dr Edward Bird
Department of Neuropathology
McLean Hospital
Belmont, Maryland 02178

Dr Walter Birkmayer
Ludwig Boltzmann Institut
für Neurochemie
Neurologische Abteilung
Versorgungsheimplatz 1
A-1130 Vienna Lainz, Austria

Dr David M. Bowen
Department of Neurochemistry
Institute of Neurology
Queen Square
London WC1N 3BG, UK

Dr Tim J. Crow
Division of Psychiatry
MRC Clinical Research Centre
Watford Road
Harrow, Middlesex HA1 3UJ, UK

Dr Piers Emson
MRC Neurochemical Pharmacology
Unit, Department of Pharmacology
Medical School, Hills Road
Cambridge CB2 2QD, UK

Dr E. S. Garnett
McMaster Division
Shedoke McMaster Hospital
Box 2000, Station A
Hamilton 28N 325, Ontario, Canada

Dr Carl-Gerhard Gottfries
Psychiatric Research Center
St. Joergen's Hospital
S-422 03 Hisings Backa, Sweden

Dr Oleh Hornykiewicz
Institute of Biochemical
Pharmacology
University of Vienna
Borschkegasse 8a
A-1090 Vienna, Austria

Dr Kenneth G. Lloyd
Synthelabo-L.E.R.S.
31, Avenue Paul Valliant Couturier
92220 Bagneux, France

Professor Toshiharu Nagatsu
Tokyo Institute of Technology
4259 Nagatsuda, Midori-ku
Yokohama, 227, Japan

Dr Peter Riederer
Ludwig Boltzmann Institute for
Clinical Neurobiology
Lainz Hospital Pav. XI
Wolkersbergenstrasse 1
A-1130 Vienna, Austria

Dr U. D. Rinne
Department of Neurology
University of Turku
SF-20520 Turku 52, Finland

Professor Merton Sandler
Department of Chemical Pathology
Bernhard Baron Memorial Research
Laboratories
Queen Charlotte's Maternity Hospital
Goldhawk Road
London W6 0XG, UK

Dr Philip Seeman
Department of Pharmacology
University of Toronto
Toronto 5, Ontario, Canada

Dr Earl Usdin
Neurosciences Research
Branch, National Institute of
Mental Health
560 Fishers Lane — Room 9C-09
Rockville, Maryland 20857

Preface

Research using human post-mortem brain tissue is performed in a number of scientific centers in the world; many find such research not only necessary but also invaluable to answer questions not only of basic neurochemistry but also of applied biochemistry, biochemical pharmacology and drug treatment.

The possibilities and limitations of neurochemical research using human brain tissue have not been discussed previously *in extenso*; a number of questions are still unresolved. Although there has recently been a 'Workshop on Dissection of Human Brain Tissue' (Vienna, 1979), a conference where research groups working in the fields of neurochemistry and pharmacology of the human brain exchanged results and techniques had not been organized prior to the 1980 CIMP Congress in Göteborg, Sweden. At that meeting, there was a Symposium on Transmitter Biochemistry of Human Brain Tissue, with discussion extended to the molecular level for diseases of the central nervous system.

Methods are discussed in this volume for biochemical analyses using post-mortem brain tissue, including how subcellular fractions (mitochondria, synaptosomes, membranes, etc.) behave in unfrozen tissue in comparison to frozen tissue and how post-mortem time, age, disease, therapy, preparation of homogenates, storage conditions, etc. influence results. Such methodological questions need to be discussed in the light of comparison between neuropathology and neurochemistry. Studies on uptake, release and receptor binding are also covered. Comparisons are made of data obtained with human brain tissue with data from animal experiments.

Animal models have their limitations in simulating psychiatric and neurological disorders; studies on schizophrenia, Parkinson's Disease, Huntington's Disease, senile dementia of Alzheimer's type, and problems of the aging brain contribute to a better understanding of the underlying pathomechanisms of such disorders and may help in developing new therapeutic strategies.

This interchange of ideas and experience by international experts allows us to take stock of knowledge on the neurochemistry of human brain tissue. We hope this important information will stimulate basic research as well as applied pharmacology.

It is now 20 years since, as a consequence of analyses of human brain tissue, a therapy was found for a neurological disease: L-Dopa

therapy for Parkinson's Disease. We are happy that Dr Birkmayer and Dr Hornykiewicz, both responsible for opening this door to human brain biochemistry and pharmacology, have accepted our invitation to contribute to this Symposium.

Peter Riederer, Earl Usdin

Abbreviations

ACE, angiotensin converting enzyme	5-HIAA, 5-hydroxyindole acetic acid
ADTN, 2-amino-6, 7-dihydroxy-1, 2,3,4-tetrahydronaphthalene	HPLC, high performance (<i>or</i> pressure) liquid chromatography
AMP, adenosine monophosphate	³ HSP, ³ H-spiroperidol
ATD, Alzheimer's-type dementia	5-HT <i>or</i> HT, serotonin
ATPase, adenosine triphosphatase	5-HTP, 5-hydroxytryptophan
BBB, blood—brain barrier	HVA, homovanillic acid
BGP, brain gastric peptide	KYN, kynurenine
CA, catecholamine(s)	MAO, monoamine oxidase
cAMP, cyclic AMP	MC, magnocellular
CAT, choline acetyltransferase	met, methionine
CBF, cerebral blood flow	MHPG, 3-methoxy-4-hydroxyphenyl-alanine
CCK, cholecystokinin	NA, noradrenaline (<i>or</i> norepinephrine)
CNS, central nervous system	NM, normetanephrine
COMT, catechol <i>O</i> -methyltransferase	NTR, neurotransmitter receptor
CSF <i>or</i> c.s.f., cerebrospinal fluid	pat., patients
DA, dopamine	PC, parvocellular
DBH, dopamine β -hydroxylase	rCBF, regional CBF
DHEC, dihydroergocryptine	RN, red nucleus
DNA, deoxyribonucleic acid	RNA, ribonucleic acid
Dopa <i>or</i> dopa <i>or</i> DOPA, dihydroxy-phenylalanine	SN, substantia nigra
DOPAC, dihydroxyphenylacetic acid	TH, tyrosine hydroxylase
EDTA, ethylenediamine tetraacetic acid	TRP, tryptophan
GABA, γ -aminobutyric acid	TRP-OH, TRP hydroxylase
GABA-T, GABA transaminase	TYR, tyrosine
GAD, glutamic acid decarboxylase	TYR-OH, TYR hydroxylase
GC, gas chromatography	VAL, valine
GRH, gonadotropin-releasing hormone	VIP, vasoactive intestinal polypeptide
H.D., Huntington's Disease	

Contents

<i>Participants</i>	ix
<i>Preface</i>	xi
<i>Abbreviations</i>	xiii
Section I: Behavior and Biochemistry: An Introductory Essay <i>Konrad Lorenz</i>	1
Section II: Basic Techniques	7
Importance of topographic neurochemistry in studying neurotransmitter systems in human brain: Critique and new data. <i>Oleh Hornykiewicz</i>	9
Brain neurotransmitter amines in cerebral ischemia and stroke. <i>K. Jellinger and P. Riederer</i>	25
[¹⁸ F]Fluoro-Dopa for the <i>in vivo</i> investigation of intracerebral dopamine metabolism. <i>E. S. Garnett, G. Firnau and C. Nahmias</i>	43
Analytical problems in post-mortem brain studies. <i>C.-G. Gottfries, Rolf Adolfsson and Bengt Winblad</i>	47
Regulation of 5-HT receptor binding as a biochemical model for pathological or functional changes in the CNS. <i>Wolfgang Wesemann, Norbert Arold, Appletree Rodden and Nina Weiner</i>	55
Section III: Enzymes and Receptors	71
Dopamine receptors in human brain: Comparison with rat and calf brain. <i>Stephen List and Philip Seeman</i>	73
Neurotransmitter enzymes and receptors in post-mortem brain in schizophrenia: Evidence that an increase in D ₂ dopamine receptors is associated with the type I syndrome. <i>T. J. Crow, F. Owen, A. J. Cross, N. Ferrier, E. C. Johnstone, R. M. McCreadie, D. G. C. Owens and M. Poulter</i>	85
Dopamine metabolism in human brain. <i>Merton Sandler, Vivette Glover, M. A. Reveley, Pauline Lax and G. Rein</i>	97
Propranolol binding in human brain: Preliminary studies. <i>Gavin P. Reynolds, Peter Riederer and Eberhard Gabriel</i>	105

Section IV: Low Molecular-Weight Compounds	113
Dopamine and noradrenaline in the magno- and parvocellular portions of the red nucleus. <i>K. Jellinger, G. P. Reynolds and P. Riederer</i>	115
Function and dysfunction of the GABA system in the human brain. <i>Kenneth G. Lloyd, C. Munari, L. Bossi, J. Bancaud, J. Talairach and P. L. Morselli</i>	127
Central aminergic function and its disturbance by hepatic disease: The current status of L-valine pharmacotherapy in metabolic coma. <i>P. Riederer, P. Kruzik, E. Kienzl, G. Kleinberger, K. Jellinger and W. Wesemann</i>	143
Antipsychotic ligand binding sites in human brain: Regional selectivity implicates involvement of multiple neurotransmitters. <i>Anne C. Andorn</i>	183
Section V: Pathological States	199
(A) HUNTINGTON'S DISEASE	199
Transmitter biochemistry of Huntington's Disease. <i>Edward D. Bird and Linda J. Kraus</i>	201
Neuropeptides in human brain: Studies on substance P, cholecystokinin, vasoactive intestinal polypeptide and methionine-enkephalin in normal human brain and in Huntington's Disease. <i>P. C. Emson, M. Rossor, S. P. Hunt, V. Clement-Jones, J. Fahrenkrug and J. Rehfeld</i>	221
(B) ALZHEIMER'S DISEASE AND SENILE DEMENTIA	235
Biogenic amines and related enzymes in normal aging, senile dementia and chronic alcoholism. <i>Bengt Winblad, Rolf Adolfsson, Sten-Magnus Aquilonius, Arvid Carlsson, Sven-Åke Eckernäs, Carl-Gerhard Gottfries, Stefan Marklund, Agneta Nordberg, Lars Orelund, Lars Svennerholm and Åsa Wiberg</i>	237
Biochemical changes in Alzheimer's Disease in relation to histopathology, clinical findings and pathogenesis. <i>D. M. Bowen, N. R. Sims and A. N. Davison</i>	253
(C) PARKINSON'S DISEASE	269
Parkinson's Disease as a model for behavioural studies in man. <i>W. Birkmayer and P. Riederer</i>	271
Biopterin in the brain of controls and patients with Parkinson's Disease and related striatal degenerative diseases: Application of new biopterin radioimmunoassay. <i>Toshiharu Nagatsu, Tokio Yamaguchi, Takeshi</i>	

<i>Kato, Takashi Sugimoto, Sadao Matsuura, Miki Akino, Ikuko Nagatsu, Reiji Iizuka and Hirotaro Narabayashi</i>	281
Catecholaminergic enzymes in Parkinson's Disease and related extrapyramidal diseases. <i>Toshiharu Nagatsu, Kazuhiro Oka, Toshifumi Yamamoto, Hiroaki Matsui, Takeshi Kato, Chosaburo Yamamoto, Ikuko Nagatsu, Reiji Iizuka and Hirotaro Narabayashi</i>	291
Brain dopamine receptors in Parkinson's Disease: Involvement with clinical features and therapeutic responses. <i>U. K. Rinne</i>	303
Summary. <i>Earl Usdin</i>	319
<i>Subject Index</i>	323

Section I
Behavior and Biochemistry:
An Introductory Essay

Behavior and Biochemistry: An Introductory Essay

KONRAD LORENZ

*Österreichische Akademie der Wissenschaften,
Institut für Vergleichende Verhaltensforschung,
A-3422 Altenberg, Austria*

It is questionable whether someone with next-to-no understanding of the content of this book should be permitted to write its preface. I can only justify this introduction by saying that one can well estimate the importance of a new research field and its results if one is able to assess the gap in our present knowledge which they help to bridge.

Many neurophysiologists and behaviorists underestimate the width of the abyss which lies between our knowledge of behavior and its underlying neurophysiology. Even if one believes in the outmoded idea that the "reflex" is the basic element of all animal and human behavior, and even if one thinks that "the nervous system of animals is nothing else but an organ for the processing and transport of information" (Neureiter, 1974) a tremendous cleft still remains between the action of a single neural element and the behavior of the whole organism. We have learnt from Erich von Holst, Kenneth Roeder and others that the neuron itself, indeed even an axon, has a complex and comprehensive inventory of spontaneous behavior. We know, too, that the reaction of an effector cell to a stimulus is described not by a single impulse but by a modulation of the frequency of continuously and spontaneously emitted impulses. As there is so much complexity at even this "simple" level, the gap between the behavior of an organism and that of its constituent elements appears much greater. Thus the research strategy of our best neuroethologists (such as F. Huber, and W. Heiligenberg) is to study relatively simple behavior in

relatively simple organisms. The gap between our present understanding of elementary neuronal and sensory functions and our ability to interpret animal and human behavior is tremendous, but it must be emphasized that it can, in principle, be bridged by the knowledge of the functions of elements and of the structures into which they are combined.

There is, however, another "hiatus" - as Nicolai Hartmann has described it. It is the inability, in our present way of thinking to overcome the basic problem of the body-mind relationship. This is in principle insoluble since the relationship between the physiological and the subjective event is, as expressed by Max Hartmann, alogical. We know that some physiological processes are generally accompanied by certain subjective phenomena, while other such processes are not consciously experienced. This relation of the physiological with the subjective is not correlated with the complexity of the process. Some simple events, such as the inflammation of tooth-pulp, have an intense subjective parallel, while some highly complex phenomena, for example computations performed by our Gestalt perception, are not only unconscious but not even accessible to introspection. Thus the old idea that simple neurosensory processes are "merely" physiological, while higher, more complex events are better explained psychologically (found in the otherwise excellent animal psychology textbook by Hempelmann) is totally false.

Provided one assumes the inherent insolubility of the body-mind problem, there are three possible attitudes that can be taken with regard to it. Firstly, one may assume a reciprocal interaction between the physiological processes and the concomittant subjected experiences. This I refuse to accept because it postulates a non-physical causation of physical events. The second assumption is that a prestabilized harmony or a parallel exists between psychological and physiological events. There are, however, limitations to "psycho-physiological parallels", since there are so very many neuro-physiological functions which do not have any subjective parallels. The third assumption is that body and mind are only two different aspects of the same reality, each defined by a different cognitive apparatus of our brain. This "identity doctrine" meets the same difficulties as that of parallelism. There is no doubt that only a few particular neurological events are accompanied by

objective phenomena. They rise above the threshold of our consciousness as does the tip of an iceberg, while its greater part remains below the surface.

In spite of this difficulty I adhere to it for the simple reason that the cognitive structures of every normal human being are dictating it. When I assert that my friend B. is sitting beside me, I mean neither the presence of his physical system accessible to physiological research, nor do I mean the unity of all his undisputed mind and his subjective phenomena, so similar to my own. What I mean is quite exactly the unity of both.

One can step aside from this problem by neglecting subjective reaction and by examining only objectively measurable animal behavior. This is the approach of the large American school of behaviorism. This narrowing of interest is justifiable when studying either simple organisms or specific and relatively simple learning mechanisms. However, in the case of man and the higher animals this exclusion of subjective experience is the greatest sin in our search for truth: as it means the refusal to accept perfectly accessible knowledge.

If one is convinced of the fundamental unity of the organisms, then it is justifiable to correlate qualitative experience with neurophysiological action. Of course, the reverse is not necessarily true. But every experience, even the most transient dream, correlates with a physiological event. There are no miracles! Even when this assertion is more religious than scientific it is nevertheless the basis of the scientific study of man.

Thus it is perhaps justifiable to say that the nervous system is more than just an organ for the processing and transport of information. Indeed, since "I" am my own nervous system, I contradict with greatest possible assurance the statement that I am "nothing else but an information processing and transport system".

Both complex and basic processes of our brain are accompanied by subjective experience. Indeed, regulatory processes occurring in the brain are able to influence our psyche to a great extent. This is important in relation to this publication, as without the observation of subjective phenomena (so despised by

behaviorists) it would hardly have been possible to have advanced so far in our understanding of the biochemical function of the brain stem. It raises our confidence in that such observation of subjective phenomena may be a reliable indicator of the excess as well as of the deficiency of certain biochemical transmitter substances, in particular in brain stem regions. The importance of this has been illustrated by the fact that through such observations and subsequent research it has been possible to correct abnormally functioning regulatory mechanisms by chemotherapy.

If it is at all possible to bridge the gap between biochemical function and behavior, then the work on transmitter abnormalities in the brain stem will be seen to be a vital contribution.